Measles Virus Glycoprotein-Pseudotyped Lentiviral Vectors Are Highly Superior to Vesicular Stomatitis Virus G Pseudotypes for Genetic Modification of Monocyte-Derived Dendritic Cells

Humbert, J.-M.; Frecha, Cecilia; Bouafia, F. Amirache; Nguyen, Tin; Boni, Sébastien; Cosset, François‐Loïc; Verhoeyen, Els; Halary, Franck

doi:10.1128/jvi.06283-11

Cited by 26 publications

(19 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LVs pseudotyped with a baboon retroviral envelope glycoprotein (BaEV) [112] or Measles virus glycoprotein [113] that do not rely on LDL-R for entry have been suggested to out-perform the VSV-g pseudotyped one in T and B cells as well as in quiescent CD34 + HSPC. Targeting LVs towards more primitive subsets of HSPC by exploiting the subset-specific expression of surface markers such as CD105 and CD133 has also shown promising results regarding preferential transduction of long-term repopulation HSC [114,115].…”

Section: Samhd1 and Dramatically Increases LV Transduction Efficiencymentioning

confidence: 99%

Cellular Innate Immunity and Restriction of Viral Infection: Implications for Lentiviral Gene Therapy in Human Hematopoietic Cells

Kajaste‐Rudnitski

Naldini

2015

Human Gene Therapy

View full text Add to dashboard Cite

Hematopoietic gene therapy has tremendous potential to treat human disease. Nevertheless, for gene therapy to be efficacious, effective gene transfer into target cells must be reached without inducing detrimental effects on their biological properties. This remains a great challenge for the field as high vector doses and prolonged ex vivo culture conditions are still required to reach significant transduction levels of clinically relevant human hematopoietic stem and progenitor cells (HSPCs), while other potential target cells such as primary macrophages can hardly be transduced. The reasons behind poor permissiveness of primary human hematopoietic cells to gene transfer partly reside in the retroviral origin of lentiviral vectors (LVs). In particular, host antiviral factors referred to as restriction factors targeting the retroviral life cycle can hamper LV transduction efficiency. Furthermore, LVs may activate innate immune sensors not only in differentiated hematopoietic cells but also in HSPCs, with potential consequences on transduction efficiency as well as their biological properties. Therefore, better understanding of the vector-host interactions in the context of hematopoietic gene transfer is important for the development of safer and more efficient gene therapy strategies. In this review, we briefly summarize the current knowledge regarding innate immune recognition of lentiviruses in primary human hematopoietic cells as well as discuss its relevance for LV-based ex vivo gene therapy approaches.

show abstract

Section: Samhd1 and Dramatically Increases LV Transduction Efficiencymentioning

confidence: 99%

Cellular Innate Immunity and Restriction of Viral Infection: Implications for Lentiviral Gene Therapy in Human Hematopoietic Cells

Kajaste‐Rudnitski

Naldini

2015

Human Gene Therapy

View full text Add to dashboard Cite

show abstract

“…Several surface molecules on DCs have been used for targeting approaches, e.g., the C-type lectin DC-SIGN interacting with the Sindbis virus envelope protein used to pseudotype LVs (16). Also the glycoproteins of the measles virus (MV) strain Edmonston with its natural tropism for the receptors CD46, nectin-4, and SLAM (signaling lymphocyte activation molecule), the last expressed on activated immune cells such as DCs (17), have been shown to be highly suited for targeting of DCs (18). Moreover, engineered MV-GPs displaying a single-chain antibody fragment directed against major histocompatibility complex class II (MHC-II) have been successfully used for targeting of APCs (19).…”

mentioning

confidence: 99%

Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response

Uhlig

Schülke

Scheuplein

et al. 2015

J Virol

View full text Add to dashboard Cite

؉ T lymphocytes are a mainstay of antitumoral immune responses, PTVs could be engineered for the transfer of specific tumor antigens provoking tailored antitumoral immunity. Therefore, PTVs can be used as safe and efficient alternatives to gene transfer vectors or live attenuated replicating vector platforms, avoiding genotoxicity or general toxicity in highly immunocompromised patients, respectively. Thereby, the potential for easy envelope exchange allows the circumventing of neutralizing antibodies, e.g., during repeated boost immunizations. V accination is the administration of one or more immunogens, the vaccine, into patients to trigger antigen-specific adaptive immune responses to prevent (prophylactic vaccination) or to treat (therapeutic vaccination) disease. Vaccines can be classified into several subtypes. Among these are live attenuated replicating vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, or recombinant vector vaccines (for review, see reference 1). Wellknown live attenuated vaccines are, e.g., those against measles (2) or mumps (3). These vaccines replicate but have been attenuated to become apathogenic. The immune responses triggered by live attenuated vaccines are similar to those induced by the pathogenic form of the microbe (4, 5) and involve both the cellular and humoral arms of the immune system. However, attenuated replicating pathogens may carry an inherent risk of reversion to the parental virulent form by in vivo passaging during vaccination, as observed for the Sabin strain used as a polio vaccine (6), or may still be pathogenic in highly immunocompromised patients (7), depending on the respective degree of attenuation of the vaccine strains. On the other hand, inoculation of solely proteinaceous antigens (such as the hepatitis B virus vaccine [8]) or antigenencoding genes (as a DNA vaccine) is regarded as safe but relatively inefficient (9).As an alternative to such vaccines, the genes encoding an antigen can be transferred into cells and thereby presented to the immune system by using recombinant vaccine vectors. For that purpose, an attenuated vector is utilized as a carrier for the antigen-encoding sequences of another pathogen. Thereby, they are

show abstract

“…Likewise, the MV-LVs, which mimicked the natural tropism of MV for T, B and dendritic cells allowed efficient transduction of these immune cells [14,[28][29][30] upon cytokine stimulation as well as in their quiescent state ( Table 1).…”

Section: Strategies To Retarget Gp Tropismmentioning

confidence: 99%

Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells

Lévy

Verhoeyen

Cosset

2015

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Measles Virus Glycoprotein-Pseudotyped Lentiviral Vectors Are Highly Superior to Vesicular Stomatitis Virus G Pseudotypes for Genetic Modification of Monocyte-Derived Dendritic Cells

Cited by 26 publications

References 90 publications

Cellular Innate Immunity and Restriction of Viral Infection: Implications for Lentiviral Gene Therapy in Human Hematopoietic Cells

Cellular Innate Immunity and Restriction of Viral Infection: Implications for Lentiviral Gene Therapy in Human Hematopoietic Cells

Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response

Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells

Contact Info

Product

Resources

About